In this episode of The Mel Robbins Podcast, Dr. Thaïs Aliabadi and Mel Robbins discuss three frequently misdiagnosed women's health conditions: PMOS, endometriosis, and PMDD. Dr. Aliabadi explains that PMOS is a metabolic disorder rooted in insulin resistance that affects multiple hormone systems, causing symptoms ranging from weight gain and acne to mood instability. She describes endometriosis as a progressive inflammatory condition that causes debilitating pain and infertility, and PMDD as a severe mood disorder triggered by normal hormonal fluctuations during the menstrual cycle.
The conversation highlights systemic failures in women's healthcare, including the fact that 77% of women report feeling dismissed by doctors. Dr. Aliabadi addresses the fertility impact of undiagnosed PMOS and endometriosis, sharing data about declining egg reserves and urging early detection. The episode provides specific diagnostic criteria and treatment options for each condition while emphasizing the importance of self-advocacy and seeking second opinions when symptoms are dismissed.

Sign up for Shortform to access the whole episode summary along with additional materials like counterarguments and context.
Dr. Thaïs Aliabadi and Mel Robbins discuss three critical women's health conditions that are frequently misdiagnosed or dismissed: PMOS, endometriosis, and PMDD.
PMOS (polyendocrine metabolic ovarian syndrome) is the updated name for PCOS, reflecting that it's primarily a metabolic disorder affecting multiple hormone systems rather than just an ovarian condition. The underlying problem is [restricted term] resistance—cells become less responsive to [restricted term], leading to high blood glucose and [restricted term] levels. This triggers the liver to convert excess glucose into inflammatory visceral fat, causing bloating, brain fog, and stubborn weight gain.
While most tissues resist [restricted term], the ovaries remain sensitive; high [restricted term] stimulates ovarian cells to overproduce [restricted term], which is toxic to follicles and prevents proper ovulation. This creates the characteristic "string-of-pearls" appearance on ultrasound and leads to irregular or absent periods.
Beyond reproductive symptoms, PMOS causes noticeable physical signs—facial and body hair, adult acne, scalp thinning—and dramatically impacts brain chemistry. Hormonal instability disrupts emotional control, leading to mood swings, anxiety, depression, binge eating, and brain fog. Patients are often misdiagnosed with psychiatric conditions rather than recognized as having a metabolic problem. Seventy-five percent of women with PMOS struggle with unexplained weight gain regardless of diet or exercise.
Diagnosis requires meeting two of three criteria: irregular ovulatory cycles (fewer than eight periods yearly), PMOS appearance on ultrasound or elevated AMH, and hyperandrogenism symptoms. Notably, elevated [restricted term] on bloodwork isn't required—many women have normal lab values despite clear symptoms. Because providers often rely solely on labs, 75% of women with PMOS never receive a diagnosis.
Treatment begins with lifestyle changes: limiting refined carbohydrates, reducing inflammatory foods, and regular exercise like post-meal walks. Medications such as [restricted term] improve [restricted term] sensitivity, helping restore metabolic and hormonal balance, resuming ovulation, and improving fertility. GLP-1 medications are considered breakthrough treatments for PMOS, directly addressing [restricted term] resistance and enabling pregnancy by reducing ovarian [restricted term] production.
Endometriosis occurs when uterine lining cells grow outside the uterus. Dr. Aliabadi explains that during menstruation, these cells travel through fallopian tubes and implant on pelvic structures—bladder, bowel, ovaries, and even the diaphragm. Robbins adds that immune dysregulation prevents clearing these cells; instead, they attach, grow nerves, and cause persistent inflammation and pain.
These implants produce their own estrogen, growing independently from normal cycles. Over time, they recruit blood vessels and nerve fibers, increasing pain. Pain severity doesn't correlate with disease stage—some with mild endometriosis experience incapacitating pain, while those with advanced disease might have only mild discomfort but face infertility. Repeated nerve stimulation causes central sensitization, amplifying pain perception dramatically.
Major symptoms include severely painful periods, pain during intercourse, chronic pelvic pain, painful bowel movements and urination, and recurrent UTIs (often with negative cultures, due to bladder implants rather than true infection). Endometriosis should be suspected when pain disrupts daily life, requires urgent care visits, or causes frequent absenteeism.
Diagnosis starts with thorough history and physical exam, followed by pelvic ultrasound to identify endometriomas ("chocolate cysts"), which indicate advanced disease and typically mean egg count and quality are affected. A new blood test, Herresolve, detects endometriosis in approximately 80% of cases; a positive confirms diagnosis, though a negative doesn't rule it out.
Treatment ranges from low-dose oral contraceptives for pain relief, to progestin IUDs that reduce inflammation, to GnRH antagonists (like Orolisa) for advanced cases—these suppress estrogen and typically make patients pain-free within two months, though they cause temporary menopausal symptoms. The gold standard is laparoscopic excision surgery, where specialists remove implants and scar tissue, restoring normal anatomy and improving fertility. However, less than 1% of U.S. gynecologists are trained for advanced endometriosis surgery, so Dr. Aliabadi strongly recommends specialist referral.
Premenstrual Dysphoric Disorder affects 3% to 5% of women and is a severe variant of PMS. Dr. Aliabadi explains that PMDD patients have normal hormone levels, but their brains react abnormally to typical menstrual cycle fluctuations.
For 10 to 14 days each month after ovulation, PMDD patients experience severe mood crashes—anxiety, depression, exhaustion, brain fog, worthlessness, and anger—often unable to get out of bed. By day three of menstruation, symptoms suddenly lift and patients return to normal, spending the next two weeks repairing relationships damaged during their symptomatic phase. This cycling causes real trauma and contributes to high suicide rates.
Diagnosis is often missed because patients see doctors during symptom-free windows and appear well. Providers dismiss their concerns, not connecting symptoms to the menstrual cycle.
Treatment involves either stopping ovulation with birth control pills like [restricted term]—which has mood-stabilizing progestin—or using SSRIs. Unlike other mood disorders, PMDD responds very well to low-dose SSRIs taken only during the premenstrual window. Dr. Aliabadi recommends [restricted term] 20mg or [restricted term] 25mg daily for 10-14 days before menstruation. For women already on SSRIs for anxiety or depression who experience premenstrual mood dips, she advises increasing the SSRI dose by 25-50% during the symptomatic window, then returning to the regular dose after the period starts.
Dr. Aliabadi and Robbins expose how systemic failures result in women being dismissed and underserved. So-called "well-woman" exams are often reduced to a pap smear and breast exam—a superficial approach leaving numerous concerns unaddressed.
In a poll of Robbins's audience, 77% of women reported feeling dismissed at doctor's appointments, knowing something was wrong but not feeling validated. Dr. Aliabadi believes the real number is higher, as many women internalize dismissal. Fifty percent of U.S. counties lack a gynecologist, forcing women to wait up to a year for appointments, only to risk dismissal when finally seen.
Women's pain is frequently minimized or attributed to stress and anxiety. Symptoms of endometriosis are dismissed as normal, leading to an average 11-year delay for diagnosis. Medical care is fragmented and fails to connect symptoms to metabolic or hormonal causes. Many young women with PMOS are directed to psychiatric care for eating disorders without identifying their underlying metabolic dysfunction, receiving psychological treatment for symptoms manifesting from hormonal disease.
Dr. Aliabadi urges women to learn the signs of PMOS, endometriosis, and PMDD to seek proper diagnosis. Women should get second or third opinions if dismissed and never accept explanations that symptoms are due to anxiety, stress, or are just "part of being a woman." Conditions like acne, irregular periods, weight gain, and mood changes are not normal and should not be dismissed.
While self-advocacy is crucial, Dr. Aliabadi stresses that individual action cannot replace systemic healthcare reform. Accessible screenings and treatments must be available for all women. Robbins concludes by highlighting the ripple effect: each woman who learns to advocate for herself can help save those she loves, potentially improving millions of lives.
Dr. Aliabadi raises awareness about the devastating fertility impact of undiagnosed PMOS and endometriosis. Female fertility is tied to egg quantity, which naturally declines with age: from 300,000-500,000 eggs at puberty to 200,000 at age 20, 100,000-150,000 at 30, 50,000-80,000 at 35, and just 10,000-30,000 at 40.
This decline accelerates drastically with reproductive inflammation, endometriosis, or endometriomas, which reduce egg quantity and severely damage quality. PMOS patients show falsely elevated AMH, appearing to have abundant egg reserves, but egg quality is often poor due to chronic inflammation from high [restricted term] and metabolic dysfunction.
Dr. Aliabadi shares alarming cases: a 34-year-old woman with undiagnosed endometriosis for 20 years had zero eggs remaining when evaluated for infertility, making biological children impossible. Another 30-year-old woman, misdiagnosed for a decade, also had no eggs left.
Her practice data reveal that 61% of PMOS patients also have endometriosis—both are leading infertility causes. When co-occurring, they create compounded fertility challenges by reducing egg count and deteriorating quality. Dr. Aliabadi insists that women diagnosed with either condition must be screened for the other.
Early detection and treatment through metabolic management, hormonal therapy, or surgery offers the best chance of preserving fertility. She urges young women to check their AMH and egg reserve before their late 30s, empowering them to make informed reproductive decisions rather than discovering diminished fertility when attempting pregnancy after delay.
1-Page Summary
PMOS, or polyendocrine metabolic ovarian syndrome, is the updated name for what was long called PCOS (polycystic ovary syndrome). The old term was misleading, as many patients do not have ovarian cysts. The new name describes the disorder more accurately: it involves dysfunction in multiple hormone systems and is rooted in metabolic issues, not merely ovary-related abnormalities.
The key underlying problem in PMOS is [restricted term] resistance. In PMOS, the body’s cells become less responsive to [restricted term]—a hormone that lets cells absorb glucose for energy—so when carbohydrates are eaten and broken down into glucose, [restricted term] is released but cells “ignore” it. As a result, glucose remains in the bloodstream, causing higher [restricted term] levels.
Persistently high [restricted term] signals the liver to turn excess glucose into visceral fat, a type of fat that gathers internally and promotes high inflammation, bloating, brain fog, and stubborn weight gain that is difficult to reverse. Meanwhile, although many tissues are resistant to [restricted term], the ovaries remain sensitive; high [restricted term] stimulates ovarian theca cells to overproduce [restricted term]. Excess [restricted term] is toxic to ovarian follicles, halting their maturation.
Instead of proper ovulation, the follicles become “frozen” partway through development, creating a “string-of-pearls” appearance on ultrasound. This inflammation and blockage prevent regular ovulation, leading to irregular or absent periods and pelvic inflammation.
PMOS’s effects go far beyond the reproductive system. Women with PMOS often have infrequent or irregular periods, typically occurring every 35-40 days or fewer than eight times yearly. Elevated androgen ([restricted term]) levels cause noticeable physical signs such as facial hair, excess body hair, persistent adult acne, and scalp hair thinning. Many patients seek dermatological treatment—like laser hair removal or acne medication—without the underlying metabolic dysfunction being identified.
Unexplained weight gain is common: 75% of PMOS patients struggle with weight regardless of their diet or exercise, experiencing cravings and low motivation due to underlying metabolic issues. In families, even sisters with similar lifestyles can show stark differences if one has PMOS.
PMOS also dramatically impacts brain chemistry. The hormonal instability—erratic estrogen, low or absent progesterone due to lack of ovulation, high inflammation, and altered [restricted term] in the prefrontal cortex—dysregulates the limbic system, disrupting emotional control. This leads to mood swings, anxiety, depression, binge eating, intense cravings, motivation loss, and brain fog. Often, patients are wrongly diagnosed with eating disorders or psychiatric conditions rather than recognized as having a metabolic problem.
Other common issues include poor sleep, heightened stress response, and metabolic complications, all rooted in hormonal imbalances and chronic inflammation. PMOS patients frequently feel “off” or not like themselves, suffering from emotional and cognitive symptoms that disrupt daily life.
Diagnosing PMOS requires meeting two out of three criteria:
It is not necessary to have elevated [restricted term] on bloodwork to receive a PMO ...
Pmos: Causes, Symptoms, Diagnosis, Treatment
Endometriosis is a progressive and often painful condition in which cells that make up the uterine lining grow outside the uterus. Dr. Thaïs Aliabadi explains that during menstruation, endometrial cells can travel through the fallopian tubes and implant on pelvic structures such as the bladder, bowel, ovaries, fallopian tubes, behind the uterus, and can even reach the diaphragm. Mel Robbins elaborates that, unlike in healthy individuals where floating endometrial cells are cleared by the immune system, those with endometriosis experience immune dysregulation that prevents removal of these cells. Instead, the immune system allows these cells to attach, grow nerves, expand, and inflame, causing persistent pain.
Once implanted, these endometrial cells become inflammatory. They thrive on estrogen and begin to produce their own estrogen through local aromatase expression, enabling them to grow independently from the body's normal cycles. Over time, the implants recruit blood vessels and more nerve fibers, increasing their ability to cause pain and inflammation.
Pain severity in endometriosis is not proportional to the surgical stage of the disease. Some with mild (stage one) endometriosis may experience severe, incapacitating pain, while others with more advanced (stage four) disease might report only mild discomfort but face infertility. The nerve fibers associated with implants fire every menstrual cycle and eventually throughout the month. This repeated stimulation causes central sensitization—wherein mild discomfort is amplified by the nervous system, so pain perceived as a "2/10" in others may be a "10/10" for someone with endometriosis.
Identifying endometriosis can be challenging due to its diverse symptoms, which significantly impact quality of life. Dr. Aliabadi lists major symptoms: severely painful periods, pain during deep penetration with intercourse, chronic pelvic pain, painful bowel movements, painful urination, and recurrent urinary tract infections (UTIs). The location of pain corresponds to where the endometrial implants and their nerve fibers are located. Patients often present with recurring pelvic pain, discomfort with urination or defecation, or pain on one side of the pelvis. Symptoms also include recurrent monthly "bladder infections"—even when urine cultures are negative—due to bladder-affecting implants rather than true infection, often leading to inappropriate antibiotic use.
Endometriosis should be suspected in women and young people with unexplained, severely painful periods, especially if pain disrupts daily life, requires urgent care visits, or leads to frequent changes in plans or absenteeism from school or work. Aliabadi emphasizes the importance of listening closely to patient histories; if someone is organizing their life around their period or experiences negative cultures with cyclical UTI symptoms, endometriosis must be considered.
Diagnosis starts with a thorough history and physical exam, followed by imaging. Pelvic ultrasound is essential—particularly for identifying endometriomas (ovarian endometriosis, or "chocolate cysts"), which have specific ultrasound findings. Presence of an endometrioma suggests advanced disease and typically means egg count and quality are affected, with potential infertility.
A new blood test, Herresolve, can now detect endometriosis in roughly 80% of cases. Results are ready within a week. A positive result confirms the diagnosis, while a negative does not rule it out. Aliabadi encourages patients to request this test as it provides leverage for further care, reducing the risk of dismissal by providers, though it must be interpreted in the context of symptoms.
Treatment for endometriosis is multi- ...
Endometriosis: Pathology, Diagnosis, and Comprehensive Treatment Strategies
Premenstrual Dysphoric Disorder (PMDD) is a severe variant of premenstrual syndrome that affects 3% to 5% of women, according to Thaïs Aliabadi. Unlike regular PMS, PMDD occurs in patients whose hormone levels are normal, but whose brains react abnormally to the typical hormonal fluctuations of the menstrual cycle.
Aliabadi explains that women with PMDD do not have abnormal hormonal profiles; rather, their brains process these hormonal changes differently, resulting in debilitating psychological symptoms.
For 10 to 14 days each month, usually after ovulation during the luteal phase, PMDD patients experience significant mood crashes. Symptoms include anxiety, depression, exhaustion, brain fog, feelings of worthlessness, irritability, and anger. Many are unable to get out of bed and their daily function is severely impacted.
As soon as menstruation begins, by day three, symptoms suddenly lift, and patients return to their normal selves. Often, the next two weeks are spent repairing relationships and addressing damage caused during the symptomatic half of the cycle.
The cycling of severe symptoms brings real trauma and contributes to high suicide rates within this group. Aliabadi describes the overnight and stark personality shifts as heartbreaking, both for patients and their families.
Diagnosis is often missed. Many patients see a doctor during their symptom-free window, at which point they appear well. Providers may dismiss their concerns, unaware that symptoms are restricted to the premenstrual phase and thus miss the connection to the menstrual cycle.
Aliabadi explains that one treatment approach is to stop ovulation and thus prevent hormonal fluctuations. [restricted term], a birth control pill with mood-stabilizing progestin, is particularly effective. Continuous use—skipping the placebo week to prevent menstruation—provides more consistent symptom relief.
Pmdd: Distinguishing Severe Mood Disorder From Normal Pms
Dr. Thais Aliabadi and Mel Robbins expose how systemic failures in healthcare result in women being dismissed, inadequately diagnosed, and severely underserved, emphasizing the urgent need for self-advocacy and structural reform.
Dr. Aliabadi points out that so-called “well-woman” exams are often reduced to a pap smear, a breast exam, maybe STD testing, and birth control—a superficial approach that leaves numerous health concerns unaddressed. She stresses that if this is all women receive, they are being dismissed and not truly cared for.
In a poll conducted with Mel Robbins’s audience, 77% of women reported leaving a doctor’s appointment feeling dismissed or unheard, knowing something was wrong but not feeling validated. Dr. Aliabadi believes the real number is even higher, as many women internalize their dismissal and become unaware that it has even occurred.
Dr. Aliabadi highlights that 50% of U.S. counties lack a gynecologist. This forces women to wait—sometimes up to a year—for appointments, only to risk being dismissed when finally seen. For those who aren't dismissed, the financial burden of care or prescriptions remains prohibitive.
Aliabadi and Robbins highlight how women’s pain is frequently minimized or attributed to stress, anxiety, or lack of sleep rather than leading to appropriate diagnostic investigation. Symptoms of serious conditions like endometriosis are dismissed as normal, leading to an average delay of 11 years for proper diagnosis.
Medical care for women is fragmented and often fails to connect symptoms to metabolic or hormonal causes. Dr. Aliabadi shares stories of patients who, after years of dismissal, find themselves unable to have children in their forties because issues like endometriosis or PMOS (Polycystic Ovarian Metabolic Syndrome) were never identified or addressed at earlier stages.
Many young women and teenagers with PMOS are funneled toward psychiatric care for eating disorders, anxiety, or depression. Their underlying metabolic dysfunction goes untreated, as providers focus on psychiatric symptoms rather than uncovering the root cause in hormonal or metabolic disease. Dr. Aliabadi describes millions of girls in eating disorder centers, where their core metabolic health issue is being missed.
Dr. Aliabadi commits to teaching women the signs and symptoms of conditions like PMOS, endometriosis, and PMDD—the leading causes of infertility—to empower them to fight for an accurate diagnosis.
Women should never settle for being dismissed. If a provider doesn ...
Dismissed Women Patients: Systemic Failures and the Need For Self-Advocacy
Dr. Thaïs Aliabadi raises critical awareness about the devastating impact of undiagnosed and untreated reproductive conditions—particularly PMOS (Polycystic Morphotype Ovarian Syndrome) and endometriosis—on fertility and egg reserve. She emphasizes the importance of understanding egg count changes, early screening, and the often-overlooked risk posed when these diseases occur separately or together.
Dr. Aliabadi explains that female fertility is tightly linked to egg quantity, which naturally declines with age. At 20 weeks of gestation in utero, a female fetus has about six to seven million eggs. This number falls to one to two million at birth, then to 300,000 to 500,000 at puberty. By age 20, only about 200,000 eggs remain; at 30, the count drops to 100,000-150,000; at 35, there are just 50,000-80,000 eggs, and by age 40, only 10,000-30,000 eggs are left. At menopause, a woman has only around 1,000 eggs. This depletion means every woman is constantly losing eggs through natural aging.
Natural age-related decline can be drastically accelerated by reproductive inflammation, endometriosis, or endometriomas. These conditions not only reduce egg quantity but also severely damage egg quality. Dr. Aliabadi states that when inflammation from endometriosis or ovarian cysts is present, the decline is much steeper and the chances of achieving pregnancy plummet.
In patients with PMOS, a related danger exists—these individuals typically present with a falsely high AMH (Anti-Müllerian Hormone) level, making it appear that they have an abundant egg reserve. However, the egg quality is often poor due to chronic ovarian inflammation driven by high [restricted term] and metabolic dysfunction. This paradox leads many PMOS patients to believe their fertility is protected when it is actually compromised in a different way.
Dr. Aliabadi shares alarming case studies to highlight catastrophic outcomes from delayed diagnosis. One woman, age 34, had unknowingly endured endometriosis for 20 years. When finally evaluated for infertility just after marriage, she had zero eggs left—her dream of biological children was no longer possible. In another case, a 30-year-old woman suffered a decade of painful periods and was referred from another country; by her first specialist visit, her egg count was also zero. Both cases underline the urgent need for early investigation to prevent irreversible fertility loss.
Dr. Aliabadi’s practice data reveal that 61% of patients diagnosed with PMOS also have endometriosis. She and Mel Robbins stress that both PMOS and endometriosis are the leading causes of infertility in women, often acting together to multiply reproductive harm.
When PMOS and endometriosis co-occur, they create compounded o ...
Fertility vs Infertility: Impact of Pmos and Endometriosis
Download the Shortform Chrome extension for your browser
